Table 5 Prevalence of use of different antihypertensive drug classes in patients with or without metabolic syndrome
|  | β-blockers | ACEIs | ARBs | CCBs | Diuretics | α1 adrenergic blockers |
|---|---|---|---|---|---|---|
No metabolic syndrome | ||||||
 Whole population (n = 62) | 23 (37.1) | 18 (29.0) | 27 (43.5) | 11 (54.8) | 32 (14.5) | 2 (3.2) |
 Only antihypertensive (n = 55) | 21 (38.2) | 15 (27.3) | 26 (47.3) | 9 (16.4) | 29 (52.7) | 1 (1.8) |
 Antihypertensive plus antidiabetic or lidip lowering drugs (n = 7) | 2 (28) | 3 (42.9) | 1 (14.3) | 2 (28.6) | 3 (42.9) | 1 (1.8) |
Metabolic syndrome | ||||||
 Whole population (n = 67) | 22 (32.8) | 21 (31.3) | 28 (41.8) | 14 (40.3) | 28 (22.4) | 5 (7.5) |
 Only antihypertensive (n = 49) | 14 (28.6) | 17 (34.7) | 19 (38.8) | 11 (22.4) | 20 (40.8) | 3 (6.1) |
 Antihypertensive plus antidiabetic or lidip lowering drugs (n = 18) | 8 (44.4) | 4 (22.2) | 9 (50.0) | 3 (16.7) | 8 (44.4) | 2 (11.1) |